Gas Prices Masked a Resilient Consumer in June: What the 0.2% Retail Sales Rise Really Means

 

Gas Prices Masked a Resilient Consumer in June: What the 0.2% Retail Sales Rise Really Means

**Headline numbers were held back by a 5.3% plunge at the pump, but core retail sales surged 0.5%. Here's the real story behind the data—and why the respite at the pump may already be over.**

---

## Introduction: The Tale of Two Retail Sales Reports

On the surface, the June retail sales report looked like a slowdown. The Commerce Department reported a modest 0.2% month-over-month increase, a notable deceleration from May's revised 1.0% jump. Headline sales came in at $768.6 billion, exactly in line with economists' expectations.

But beneath that modest headline lies a much more interesting story.

Excluding gasoline stations—where receipts plunged 5.3% in the sharpest monthly decline since 2022—retail sales rose a robust 0.7%. And "control-group" sales, which feed directly into the government's calculation of GDP, rose 0.5%. For context, the control group excludes food services, auto dealers, building materials stores, and gasoline stations, providing the cleanest read on underlying consumer spending.

The numbers are clear: **headline weakness was almost entirely a gas-station story**. And that distinction matters enormously for how we interpret the health of the American consumer.

---

## The Gasoline Factor: A 50-Cent Tax Cut

The primary drag on headline retail sales was a dramatic drop in gasoline prices. The national average price at the pump fell roughly **50 cents a gallon** in June, from $4.61 in May to $4.18. This decline was driven by a brief, shaky ceasefire between the United States and Iran, which sent oil prices temporarily lower.

The result: gasoline station receipts fell 5.3% in June. That's the sharpest monthly decline since 2022.

"Lower gasoline prices mean June retail sales understate the strength of demand," Bloomberg Economics' Eliza Winger said in a note. "The roughly 50-cent decline in gasoline prices acted like a tax cut for consumers, freeing up cash for other purchases," added Elizabeth Renter, senior economist at NerdWallet.

In other words: consumers didn't stop spending. They just spent less at the pump—and redirected those savings elsewhere.

---

## Where the Money Went: A Resilient Consumer in Action

When you strip away the gas-station noise, a picture of remarkable consumer resilience emerges.

**Online Sales: +1.9%**

Nonstore retailers jumped 1.9%, the biggest increase in nearly a year. This was fueled in large part by Amazon's Prime Day event, which ran from June 23 through June 26. Adobe Inc. reported that online spending across all retailers was up during Prime Day compared with last year's event.

**Motor Vehicles and Parts: Strongest Gain Since July 2025**

Outlays at auto dealers jumped nearly 2% in June. Buying a car is a big financial decision that tends to reflect confidence in the economy. The jump in auto sales suggests that despite high prices and interest rates, consumers are still willing to make major purchases.

**Sporting Goods and Hobby Stores: +1.3%**

Business at sporting goods, hobby, musical instrument, and book stores was up 1.3%, helped by spending around the FIFA World Cup. The tournament, co-hosted by the U.S., Canada, and Mexico, provided a boost to discretionary categories.

**Electronics and Appliance Stores: Also Rose**

Other discretionary categories, such as electronic and appliance stores, also posted gains. This suggests that consumers are still willing to spend on big-ticket items when they have the means.

**Restaurants and Bars: Edged Up**

The lone services category in the retail report—restaurants and bars—edged up 0.1%. While modest, this represents continued spending on experiences despite economic uncertainty.

---

## The Core Story: Control-Group Sales Rose 0.5%

For economists, the most important number in the report is the "control-group" sales figure—the measure that feeds into the government's calculation of goods spending for GDP.

The control group rose **0.5% in June**, marking the sixth consecutive increase. This was in line with expectations and followed an upwardly revised 0.8% rise in May.

**What the control group includes:**

- General merchandise stores

- Clothing and accessories stores

- Furniture and home furnishing stores

- Electronics and appliance stores

- Sporting goods, hobby, and book stores

- Nonstore retailers (e-commerce)

- Food and beverage stores

**What it excludes:**

- Motor vehicles and parts

- Gasoline stations

- Building materials

- Food services and drinking places

By excluding the most volatile categories, the control group provides the cleanest read on underlying consumer demand. And at 0.5%, it suggests that **core consumer spending remains robust**.

---

## The Income Divide: A K-Shaped Recovery

The retail sales report also highlighted the growing divergence between higher- and lower-income households—a trend that has been building for years.

**Higher-income households continue to drive spending.** They've seen their wealth boosted by a stock market rally, and they're less affected by inflation at the grocery store and the pump.

**Lower-income households are trading down.** Bank of America card data showed that lower-income families have traded down "five times faster at discount apparel stores than higher-income households so far in 2026". They're increasingly looking to general merchandise stores for deals and discounts.

"Price-conscious consumers are increasingly looking to general merchandise stores for deals and discounts," a Bank of America Institute report noted.

**Spending picked up across income groups in June.** Bank of America card data showed spending picked up steam across income groups in June, with lower-income households in particular benefiting from reduced prices at the pump. This suggests that the temporary ceasefire provided a meaningful boost to lower-income families who spend a larger share of their income on gasoline.

---

## The Economic Context: A Resilient but Cautious Consumer

The June retail sales report arrives amid a complex economic backdrop:

**Inflation is cooling—but prices remain high.** Consumer prices dropped 0.4% from May to June, the largest monthly drop in four years. The annual inflation rate declined to 3.5%, down from 4.2% in May. But prices are still more than 25% higher than five years ago. As Ryan Sweet, chief global economist at Oxford Economics, put it: "A lower inflation rate doesn't mean prices are falling — it just means they're rising more slowly".

**The labor market is cooling but remains solid.** Nonfarm payrolls have averaged 177,000 per month over the past three months, above the roughly 100,000 breakeven rate. And applications for unemployment benefits fell last week to 208,000, the lowest level since May.

**Consumer confidence is improving—but still negative.** A report from the Conference Board showed that Americans' attitudes toward the economy improved slightly in June as gas prices declined, but their outlook is still mostly negative by historical standards.

**The Iran ceasefire was short-lived.** The respite in gas prices may prove temporary. The U.S. and Iran have renewed attacks on one another, driving up oil prices and once again disrupting shipping through the Strait of Hormuz.

---

## What This Means for the Federal Reserve

The retail sales data provides some support for the view that consumer spending can hold up even as the labor market shows signs of cooling. This gives the Federal Reserve room to maintain its current stance while it assesses whether disinflation can sustain.

Fed Governor Chris Waller said this week the central bank needs to see the disinflationary trend hold over several months before calling off further tightening. Markets currently price one more rate increase this year, with the next decision due July 29.

---

## The Human Element: What This Means for You

**For the average American consumer**, the June report is a mixed bag. If you drive a lot, you probably noticed the drop in gas prices—and you may have used those savings to buy something else. But if you're in a lower-income household, you're still feeling the pinch of higher prices for everyday goods, even if the rate of inflation is slowing.

Sarah Williamson, a 27-year-old software support engineer in Raleigh, North Carolina, told the Associated Press that she feels financially secure given her stable job, but increasing costs of food and gas are making her pull back on frivolous spending. "I shop less overall as a hobby," she said. She's buying whole cantaloupes instead of pre-cut fruit to save money, and she's careful about buying clothing for herself.

**For small business owners**, the data offers a cautiously optimistic picture. Brian Reynolds, CEO of Just For Teens, a skincare line aimed at preteens and teens, noted that his low-price products—including $5 pimple patches—are "in the sweet spot of retailing right now". His brand is expanding to 10,000 Dollar General stores from about 4,000 late last year.

**For investors**, the retail sales report confirms that the consumer remains resilient—but also that the recovery is uneven. Higher-income households continue to drive spending, while lower-income families are trading down to discount stores. The Fed will be watching closely to see if the disinflationary trend holds.

---

## The Cloud on the Horizon: The Iran Conflict Resumes

The most significant risk to the consumer outlook is the resumption of the Iran conflict. The temporary ceasefire that drove gas prices lower in June has collapsed, and the U.S. and Iran have renewed attacks on one another.

President Donald Trump announced a new blockade in the Strait of Hormuz, a key shipping route for about one-fifth of the world's oil. The increase threatens to unravel at least some of the progress that occurred last month.

If gas prices rise again—and they already are—the respite that consumers enjoyed in June could be short-lived. For lower-income households in particular, a return to $4.61-per-gallon gasoline would be a significant blow to their spending power.

---

## Frequently Asked Questions

### Q: What were the headline retail sales numbers for June 2026?

A: Retail sales rose 0.2% month-over-month to $768.6 billion, in line with economists' expectations. This followed an upwardly revised 1.0% increase in May. Year-over-year, sales were up 6.7%.

### Q: Why did retail sales growth slow so much from May?

A: The slowdown was largely driven by a sharp 5.3% drop in gasoline station receipts, as gas prices fell about 50 cents a gallon in June. Excluding gas stations, retail sales rose a robust 0.7%.

### Q: What is the "control group" and why does it matter?

A: The control group is a measure of core retail sales that excludes motor vehicles, gasoline stations, building materials, and food services. It feeds directly into the government's calculation of GDP and provides the cleanest read on underlying consumer spending. It rose 0.5% in June.

### Q: Did consumers actually slow their spending in June?

A: Not really. While headline growth slowed, the underlying data shows that consumers remained resilient. Online sales jumped 1.9%, auto sales posted their strongest gain since July 2025, and sporting goods stores rose 1.3%. The headline weakness was almost entirely a gas-station story.

### Q: Why did gas prices fall in June?

A: Gas prices fell because of a temporary ceasefire between the U.S. and Iran, which sent oil prices lower. The national average pump price dropped roughly 50 cents a gallon.

### Q: Will gas prices stay low?

A: Probably not. The ceasefire has collapsed, and the U.S. and Iran have renewed attacks on one another. Oil prices are rising again, which will likely push gasoline prices higher in the coming weeks.

### Q: What does this mean for the Federal Reserve?

A: The data provides support for the view that consumer spending can hold up even as the labor market cools. This gives the Fed room to maintain its current stance while assessing whether disinflation can sustain. Markets currently price one more rate increase this year.

---

## Conclusion: A Resilient Consumer—for Now

The June retail sales report tells a story of a consumer that is resilient but cautious. Headline growth of 0.2% masked a 5.3% plunge at the pump and a robust 0.5% rise in core spending. Cheaper gas freed up cash for other purchases, and consumers responded by buying more cars, more online goods, and more sporting goods.

But the respite at the pump may already be over. The ceasefire has collapsed, and gas prices are rising again. For lower-income households in particular, the return of higher energy costs could be a significant blow to their spending power.

The economy continues to grow, layoffs are low, and businesses are investing heavily in new technologies. As one MarketWatch analysis put it: "Americans are spending more than enough to keep the economy out of danger".

But the uncertainty from the Middle East war, high inflation, and the fading benefits of generous government tax refunds suggest that the consumer's resilience will continue to be tested.

👎

Read more

The $315 Pill That Could Save Your Heart: FDA Approves First Oral Drug That Slashes Cholesterol to "Impossibly Low" Levels

 

The $315 Pill That Could Save Your Heart: FDA Approves First Oral Drug That Slashes Cholesterol to "Impossibly Low" Levels

**For the first time in history, patients can now pop a daily pill that lowers "bad" LDL cholesterol by up to 60%—matching the power of expensive injectables at half the cost. The era of the statin may finally be over.**

---

## Introduction: The End of an Era

For nearly 40 years, statins have been the undisputed gold standard for cholesterol management. Since Merck discovered lovastatin—the first statin to gain FDA approval, back in 1987—these drugs have saved countless lives by lowering LDL cholesterol and reducing the risk of heart attacks and strokes. But even the most powerful statins have their limits. They block an enzyme the liver uses to make cholesterol, but they can only take patients so far. For millions of Americans, statins alone aren't enough to reach the aggressive new LDL targets recommended by the American Heart Association and the American College of Cardiology.

That all changed on July 16, 2026.

The U.S. Food and Drug Administration approved **Lipfendra (enlicitide)** , the first-ever oral PCSK9 inhibitor, for adults with high cholesterol. It's a once-daily pill that can slash LDL cholesterol by up to 60%—far beyond what statins can achieve. And it's a fraction of the cost of existing injectable PCSK9 inhibitors, which have been available for years but never achieved widespread adoption due to high prices and the inconvenience of injections.

**For the first time, patients can get injectable-level cholesterol reduction from a pill they can take at home.**

---

## The Numbers That Matter: A 60% Plunge in "Bad" Cholesterol

To understand why this approval is such a big deal, you have to understand the numbers.

Most adults have LDL cholesterol levels above 100 mg/dL. That's considered borderline high. But cardiologists now recommend that patients at risk of heart attack or stroke aim for LDL levels **below 70**—and for people at high risk, the target is **below 55**. Statins can get some patients there, but not all.

Lipfendra can.

In two phase 3 clinical trials involving 3,207 adults with severe hypercholesterolemia—including those with an inherited condition called heterozygous familial hypercholesterolemia (HeFH)—the results were striking:

| Trial Population | Baseline LDL | LDL Reduction vs. Placebo | Target Achievement |

|------------------|--------------|---------------------------|-------------------|

| High-risk/ASCVD patients | 96 mg/dL | **-56%** | 70.3% achieved LDL < 70 mg/dL |

| HeFH patients | 119 mg/dL | **-59%** | 67.5% achieved LDL < 55 mg/dL |

In plain English: **Lipfendra reduced "bad" cholesterol by 56% to 59% compared to placebo**. In the high-risk trial, more than **70% of patients** achieved an LDL level below 70 mg/dL, and nearly 68% got below 55 mg/dL—the new aggressive targets for high-risk patients.

The drug also lowered other dangerous lipids, including non-HDL cholesterol by 53.4%, apolipoprotein B by 50.3%, and lipoprotein(a) by 28.2%. These are all markers that cardiologists use to assess cardiovascular risk.

**The bottom line:** Lipfendra can take patients to cholesterol levels that were previously only achievable with expensive, inconvenient injectable drugs—or not achievable at all.

---

## How It Works: The PCSK9 Pathway

To understand why Lipfendra is such a breakthrough, you need to understand the biology.

Your liver produces a protein called **PCSK9** that essentially destroys the LDL receptors on the surface of your liver cells. Those receptors are responsible for clearing "bad" cholesterol from your blood. The more PCSK9 you have, the fewer receptors you have, and the more cholesterol stays in your bloodstream.

Lipfendra is a **macrocyclic peptide**—a molecule designed to bind to circulating PCSK9 and block its interaction with the LDL receptor. By blocking PCSK9, it prevents the destruction of LDL receptors, allowing more receptors to remain on the surface of liver cells to clear LDL-C from the blood.

In other words: **Lipfendra unblocks your body's natural cholesterol-clearing machinery.**

This is the same mechanism used by injectable PCSK9 inhibitors like Amgen's Repatha and Regeneron's Praluent, which have been available for a decade. But those drugs require subcutaneous injections—often monthly or biweekly—and have list prices that can exceed $600 per month. Lipfendra is a pill you take once a day, and it costs **$315 for a 30-day supply**.

**The "same known pathway" as the injectables, but in a pill form that costs half as much**.

---

## The Price Point: A Game-Changer for Access

One of the biggest barriers to PCSK9 inhibitors has been cost. Injectable PCSK9 drugs like Repatha and Praluent have list prices that can exceed $600 per month, and while insurance coverage has improved, many patients still face high copays or prior authorization hurdles.

Lipfendra's list price is **$315 per month**—roughly half that of the injectable alternatives. It will also be available through the direct-to-patient TrumpRx program, which could further reduce out-of-pocket costs for eligible patients.

Merck's strategy is clear: **price it lower than the competition to drive adoption and capture market share.** Analysts expect Lipfendra to reach peak annual sales of **$5 billion**, and some have suggested "tens of billions of dollars" in potential.

For patients who have been taking injectable PCSK9 inhibitors, the switch could mean significant cost savings and greater convenience. For patients who couldn't afford the injectables, Lipfendra could be the first time they can access this level of cholesterol reduction.

---

## The Human Element: What This Means for Patients

### For the Patient Who Can't Tolerate Statins

Up to 10% of patients experience muscle pain or other side effects from statins. For them, the options have been limited. Ezetimibe and bempedoic acid can help, but they only lower LDL by about 20%. Lipfendra offers a completely different mechanism—and it can be used in patients who are already taking statins, or potentially as an alternative for those who can't tolerate them.

### For the Patient with Familial Hypercholesterolemia

HeFH is an inherited condition that causes extremely high cholesterol levels from birth. Patients with HeFH often have LDL levels above 190 mg/dL and are at dramatically increased risk of early heart attacks. In the HeFH trial, patients had an average baseline LDL of 119 mg/dL—even while already taking maximally tolerated statin therapy. Lipfendra lowered their LDL by 59%.

### For the Patient at High Risk

For patients who have already had a heart attack or stroke—or who are at high risk for one—the new AHA/ACC guidelines recommend LDL targets below 55 mg/dL. In the high-risk trial, 67.5% of Lipfendra-treated patients achieved that target, compared to just 1.2% of patients on placebo.

### The Human Emotions Behind the Headlines

- **The patient**: You've been on statins for years. Your LDL is still above 100. Your doctor has been talking about injectable PCSK9 inhibitors, but they're expensive and you hate needles. Now there's a pill.

- **The cardiologist**: You've been waiting for this moment. You've seen patients struggle with injectables, miss doses, or simply give up. A pill changes everything.

- **The pharmacist**: You're about to see a flood of new prescriptions. You need to know the fasting requirements and the interactions.

- **The primary care doctor**: You've been managing your patients' cholesterol for decades. This is the biggest change in cholesterol management since statins.

---

## The Catch: Fasting, Food Interactions, and Side Effects

No drug is perfect, and Lipfendra has its limitations.

**The fasting requirement is strict.** Patients must take the tablet in the morning on an empty stomach and avoid food or beverages other than water for **30 minutes after dosing**. It also requires an **eight-hour fast before it can be taken**. This challenging regime raises potential questions about patient compliance.

**The side effects are mild.** In the HeFH trial, the most common adverse events occurring more frequently with Lipfendra than placebo were **diarrhea and dizziness**. Adverse event rates were similar between treatment groups overall, and discontinuation rates were comparable between Lipfendra and placebo.

**The big unknown:** While the trials showed that Lipfendra provides significant reductions in atherogenic lipoproteins, **it is not yet known if the treatment can reduce the risk of cardiovascular morbidity and mortality**. Merck is conducting ongoing trials to determine whether the drug can actually prevent heart attacks and strokes. This is a critical distinction: lowering cholesterol is a surrogate endpoint; preventing cardiovascular events is the real goal.

---

## The Bigger Picture: What This Means for Merck

For Merck, Lipfendra is more than just a new drug—it's a **strategic lifeline**.

The company's blockbuster cancer treatment Keytruda is set to lose key patent protections starting in 2028, exposing the company to competition from biosimilar versions. Keytruda generated $31.7 billion—**55% of Merck's total revenue**—last year. The company desperately needs new revenue streams to fill the gap.

Lipfendra is expected to reach peak annual sales of **$5 billion**, and some analysts have suggested "tens of billions of dollars" in potential. Merck's stock was up **3%** on the approval news.

The company also received a **Priority Review** designation for Lipfendra, which is intended to slash review periods for drugs that are critical to public health or national security. The FDA Commissioner's National Priority Voucher program approved the drug in just 1-2 months, rather than the standard 6-12 months.

**Lipfendra is Merck's best hope for replacing Keytruda's revenue.** And with a pill that's cheaper, more convenient, and just as effective as injectable alternatives, it has the potential to reshape the entire cholesterol management market.

---

## What This Means for the Cholesterol Drug Market

### The Injectable PCSK9 Market Is in Trouble

Injectable PCSK9 inhibitors like Repatha and Praluent have been on the market for a decade, but they've never achieved the blockbuster sales that analysts once predicted. The reasons are clear: high prices, insurance hurdles, and patient reluctance to use injectable drugs.

Lipfendra addresses all three problems. It's cheaper (half the price), it's a pill (no needles), and it's available through a direct-to-patient program (TrumpRx). **For patients who have been taking injectable PCSK9 inhibitors, the switch to a cheaper, more convenient pill is almost inevitable.**

### The Statin Market Is Under Pressure

Statins have been the standard of care for cholesterol management for nearly 40 years. They're cheap, generic, and effective. But they can only lower LDL by about 30-50% at maximum doses. For patients who need to get below 70 or 55 mg/dL, statins alone often aren't enough.

Lipfendra is a **complement**, not a replacement, for statins. It's approved for use in patients who are **already taking maximally tolerated statin therapy**. But it could also be used as an alternative for patients who can't tolerate statins—and that could put pressure on the statin market over time.

### The Oral PCSK9 Era Has Arrived

Lipfendra is the first oral PCSK9 inhibitor, but it won't be the last. Other companies are developing oral PCSK9 candidates, and Merck's approval validates the entire class. **Within five years, the PCSK9 market could shift from injectables to pills.**

---

## Frequently Asked Questions

### Q: What is Lipfendra?

Lipfendra (enlicitide) is the first oral PCSK9 inhibitor approved by the FDA. It's a once-daily pill that lowers "bad" LDL cholesterol by up to 60%.

### Q: How does it work?

Lipfendra blocks the PCSK9 protein, which normally destroys LDL receptors on liver cells. By blocking PCSK9, it allows more LDL receptors to remain on the surface of liver cells to clear cholesterol from the blood.

### Q: How much does it cost?

Lipfendra has a list price of **$315 for a 30-day supply**—roughly half the cost of injectable PCSK9 inhibitors.

### Q: Who is it for?

Lipfendra is approved for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), who are already taking maximally tolerated statin therapy.

### Q: How effective is it?

In clinical trials, Lipfendra lowered LDL cholesterol by **56% to 59%** compared to placebo. More than 70% of patients achieved LDL levels below 70 mg/dL.

### Q: Does it have side effects?

The most common side effects are **diarrhea and dizziness**. Adverse event rates were similar between Lipfendra and placebo, and discontinuation rates were comparable.

### Q: Does it require fasting?

Yes. Patients must take it in the morning on an empty stomach and avoid food or beverages other than water for **30 minutes after dosing**. It also requires an eight-hour fast before it can be taken.

### Q: Can it prevent heart attacks?

We don't know yet. While the drug lowers cholesterol, Merck is conducting ongoing trials to determine if it can reduce the risk of cardiovascular morbidity and mortality.

### Q: Is it better than statins?

It's different. Lipfendra works through a completely different mechanism than statins. It's not a replacement for statins—it's approved for use in patients already taking statins. But it can lower cholesterol far below what statins can achieve alone.

### Q: When will it be available?

The FDA approved Lipfendra on July 16, 2026. Merck says it will be available soon through the direct-to-patient TrumpRx program.

---

## Conclusion: A New Era in Cholesterol Management

The FDA approval of Lipfendra is a watershed moment in cardiovascular medicine. For the first time, patients have access to a once-daily pill that can lower "bad" cholesterol by up to 60%—matching the power of expensive injectable drugs at half the cost.

This is not just a new drug. It's a new paradigm.

Statins have been the backbone of cholesterol management for nearly 40 years. They're effective, but they have limits. For millions of patients who can't reach their LDL targets—or who can't tolerate statins at all—Lipfendra offers a completely new path forward.

The drug works through a different mechanism than statins. It's a pill, not an injection. It's half the price of injectable alternatives. And it's available through a direct-to-patient program that could make it accessible to millions.

Of course, there are caveats. The fasting requirements are strict. We don't yet know if the drug can actually prevent heart attacks and strokes. And the drug's effectiveness in "real-world" patients—outside the controlled environment of clinical trials—remains to be seen.

But for patients who have been waiting for a better option—who have struggled with statin side effects, who couldn't afford injectable PCSK9 inhibitors, or who simply couldn't get their cholesterol low enough—Lipfendra is a game-changer.

As cardiologist Eric Topol of the Scripps Research Institute put it: **"It is good to have an FDA-approved pill that works through the same known pathway and achieves LDL lowering comparable to the injectable PCSK9 drug inhibitors"**.

The era of the injectable PCSK9 inhibitor may be ending. The era of the oral PCSK9 inhibitor has just begun. And for millions of Americans at risk of heart disease, that's a development worth celebrating.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical advice. Lipfendra (enlicitide) is a prescription medication that should only be taken under the supervision of a qualified healthcare provider. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Drug pricing, availability, and clinical trial data are subject to change. You should consult with your doctor or other qualified healthcare professional before starting, stopping, or changing any medication.

---

*Published: July 16, 2026*

-Read more --

**Tags:** Lipfendra, enlicitide, PCSK9 inhibitor, cholesterol medication, FDA approval, LDL cholesterol, Merck, heart disease, statins, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease, cholesterol pill, oral PCSK9, Repatha, Praluent, TrumpRx, Keytruda, cholesterol management, heart attack prevention

Apple vs. Nvidia: One Is Growing 10x Faster and Trades Cheaper. The Better AI Dividend Stock Is Clear.

 

Apple vs. Nvidia: One Is Growing 10x Faster and Trades Cheaper. The Better AI Dividend Stock Is Clear.

**Nvidia's revenue is growing at nearly five times Apple's rate, yet Apple trades at a higher P/E multiple. One of these tech titans offers superior growth, a cheaper valuation, and a more attractive dividend. The choice for long-term investors isn't as complicated as it seems.**

---

## Introduction: The Market Cap Race That Masks a Deeper Truth

The financial media is obsessed with one question: **Will Apple overtake Nvidia as the world's most valuable company?**

Apple is about 4% away from a $5 trillion market cap, and Nvidia currently holds the crown at $5.14 trillion. The gap has narrowed from $1.37 trillion in August 2025 to roughly $320 billion today. Apple shares have rallied 20% in 2026, hitting record after record.

But here's the problem with obsessing over market cap: **it tells you almost nothing about which stock is the better investment.**

When you look past the headline numbers, a clearer picture emerges. Nvidia is growing revenue at nearly five times Apple's rate, yet it trades at a cheaper valuation. And when it comes to dividends, one of these stocks offers a clear advantage that most investors are overlooking.

Let's break down the numbers.

---

## The Numbers That Matter: Growth, Valuation, and Dividends

### Revenue Growth: Nvidia Is in a Different League

| Metric | Apple | Nvidia |

|--------|-------|--------|

| **Latest Quarterly Revenue** | $111.2B | $81.6B |

| **Revenue Growth (YoY)** | ~17% | **85%** |

| **Data Center Revenue** | — | $75.25B (92% of total) |

The numbers are staggering. Nvidia's revenue grew 85% year-over-year to $81.6 billion, with data center revenue — the engine of the AI boom — reaching $75.25 billion. Apple's 17% growth is impressive for a company of its size, but it's less than one-fifth of Nvidia's growth rate.

Nvidia's gross margin sits around **75%**, while Apple's is roughly **48%**. The chipmaker is generating nearly $49 billion in free cash flow per quarter.

### Valuation: The Faster-Growing Stock Is Cheaper

| Metric | Apple | Nvidia |

|--------|-------|--------|

| **P/E Ratio** | ~37x | ~30x |

| **Market Cap** | ~$4.81T | ~$5.14T |

| **Forward P/E** | Premium | ~23x |

Here's the paradox: **Apple, the slower-growing company, trades at a higher multiple than Nvidia.** Apple commands a premium of roughly 37 times earnings, while Nvidia — growing at nearly five times the rate — trades at about 30 times earnings.

Some analysts believe Nvidia's forward P/E has compressed to as low as **23 times earnings**, despite 85% revenue growth. That's a remarkable disconnect: the company with dramatically superior growth is trading at a discount to its slower-growing peer.

### Dividends: One of These Stocks Is a Clear Winner

| Metric | Apple | Nvidia |

|--------|-------|--------|

| **Annual Dividend** | $1.08 | $0.28 |

| **Dividend Yield** | 0.33% | 0.14% |

| **Recent Increase** | 4% | — |

Both companies recently raised their dividends. Apple announced a 4% quarterly dividend increase to $0.27 per share. Nvidia's dividend stands at just $0.28 annually, yielding roughly 0.14%.

Neither stock is a "dividend play" in the traditional sense — yields are modest for both — but Apple offers nearly **2.5 times the dividend yield** of Nvidia. For investors seeking income alongside growth, Apple has a clear edge.

---

## Nvidia's Case: The AI Rocket Ship

Nvidia is arguably the biggest beneficiary of the AI revolution. The company's Blackwell architecture is in exceptionally strong demand, with adoption spanning hyperscalers, cloud providers, enterprises, AI startups, and sovereign customers. The company is expanding beyond GPUs with its Vera CPU platform, opening new growth opportunities in data center computing.

**Why Nvidia could be the better buy:**

- **85% revenue growth** with data center revenue nearly doubling year-over-year

- **75% gross margins** — among the highest in the industry

- **$75 billion+ in quarterly data center revenue** — the engine of the AI boom

- **~$49 billion in quarterly free cash flow**

- **Cheaper valuation** than Apple on a P/E basis

The risk? Nvidia's stock is at the mercy of AI sentiment, which has turned jumpy on worries about how much the AI build-out will cost. Investors are questioning whether the big cloud companies can keep funding an AI build-out this expensive. Nvidia doesn't report again until late August, so it has no company catalyst this month.

---

## Apple's Case: The Ecosystem Fortress

Apple's edge is a less cyclical business with a durable growth opportunity. The company is seen as a bigger AI beneficiary deeper into the AI boom's maturity, when on-device AI features become more important.

**Why Apple could be the better buy:**

- **2.5 billion active devices** — a massive platform for recurring revenue

- **Services revenue at an all-time high of ~$31 billion**

- **$147 billion in cash and marketable securities**

- **Less cyclical and volatile** than chipmakers

- **A catalyst on the calendar**: July 30 earnings report, with guidance for 14% to 17% revenue growth

Apple's premium valuation is understandable: its earnings are steadier than Nvidia's, its services arm throws off high-margin recurring revenue, and it carries far less cyclicality than a chipmaker sitting near what some investors fear is the top of a spending boom.

---

## The Verdict: Which Stock Is the Better AI Dividend Investment?

The answer depends on your investment goals:

**For pure growth investors:** Nvidia is the clear winner. The company is growing at 85%, dominating the AI infrastructure market, and trading at a cheaper valuation than its slower-growing peer. If the AI boom continues, Nvidia's earnings and stock price could continue to surge.

**For income-focused investors:** Apple offers nearly 2.5 times the dividend yield of Nvidia. Combined with its fortress balance sheet, massive installed base, and steady services revenue, Apple provides a more predictable income stream.

**For balanced portfolios:** Both stocks deserve consideration. As one analyst put it, investors should "buy Nvidia for AI-driven upside and Apple for durability". The two companies offer complementary strengths: Nvidia provides explosive growth, while Apple delivers stability and income.

---

## Frequently Asked Questions

### Q: Which company is growing faster?

A: Nvidia is growing significantly faster. Its latest quarterly revenue grew **85% year-over-year**, while Apple's grew about **17%**.

### Q: Which stock is cheaper?

A: Nvidia trades at about **30 times earnings** (or as low as 23 times forward earnings), while Apple trades at about **37 times earnings**. The faster-growing company is actually cheaper.

### Q: Which stock has the better dividend?

A: Apple has a significantly better dividend. Apple yields **0.33%** with a $1.08 annual dividend, while Nvidia yields just **0.14%** with a $0.28 annual dividend.

### Q: Is Apple about to overtake Nvidia in market cap?

A: Apple is about **4% away** from a $5 trillion market cap. The company needs to rise from roughly $327 to $340 per share to reach the milestone.

### Q: What are the risks for Nvidia?

A: The main risk is that AI spending slows. Investors are worried that cloud companies may not be able to sustain the expensive AI build-out. Nvidia is also exposed to chip stock volatility.

### Q: What are the risks for Apple?

A: Apple's main risk is slower growth. The company is growing at 17% — impressive for its size, but far below Nvidia's 85%. It also trades at a premium valuation.

---

## Conclusion: Growth, Value, or Income — The Choice Is Yours

The numbers tell a clear story:

**Nvidia offers superior growth (85% vs. 17%), a cheaper valuation (30x vs. 37x P/E), and dominates the AI infrastructure market.** It's the purest play on the AI revolution.

**Apple offers stability, a massive ecosystem of 2.5 billion devices, steady services revenue, and a significantly better dividend.** It's the safer, income-generating choice.

The market cap race between these two titans is fascinating, but it shouldn't drive your investment decision. One company is growing nearly five times faster and trades cheaper. The other offers a higher dividend, a fortress balance sheet, and less volatility.

The better AI dividend stock is clear — **but only once you know what you're looking for.**

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and company performance are subject to rapid change. Past performance is not indicative of future results. All investments carry risk, including the potential loss of principal. You should consult with a qualified financial advisor before making any investment decisions. The views expressed in this article are those of the author and do not constitute a recommendation to buy or sell any security.

---

*Published: July 16, 2026*

--Read more-

**Tags:** Apple, AAPL, Nvidia, NVDA, AI stocks, dividend stocks, stock comparison, growth stocks, value investing, technology stocks, Magnificent Seven, AI infrastructure, semiconductor stocks, consumer tech, investment analysis, stock valuation, dividend yield, market cap, $5 trillion, tech investing

Prediction: Apple Will Soon Surpass Nvidia's $5 Trillion Market Cap to Become the World's Most Valuable Company. The Reason Is Hiding in Plain Sight.

 Prediction: Apple Will Soon Surpass Nvidia's $5 Trillion Market Cap to Become the World's Most Valuable Company. The Reason Is Hiding in Plain Sight.

**Two catalysts could send the iPhone maker higher—and they're already in motion.**

---

## Introduction: The Crown Is About to Change Heads

For much of the past two years, the AI revolution has had one undisputed king. Nvidia became the first company in history to reach a $5 trillion market capitalization in October 2025, cementing its status as the engine of the artificial intelligence boom. The chipmaker's data center revenue grew at triple-digit rates for multiple quarters, and investors rewarded the companies building AI infrastructure.

But the market is beginning to recognize that the biggest opportunity may lie with the companies that turn AI into products consumers use every day. And that's where Apple comes in.

On July 13, 2026, Apple shares reached a new all-time high, pushing the company's market capitalization past **$4.8 trillion** and within striking distance of $5 trillion. As of mid-July, the gap between Apple and Nvidia had narrowed to roughly **$190 billion to $320 billion**—just 4% to 7%. Apple has gained **20%** so far in 2026, doubling the S&P 500's 10% rise, and is now the best performer among the Magnificent Seven.

I predict the iPhone maker will soon overtake Nvidia to once again wear the crown as the world's most valuable company. The reason is hiding in plain sight: **Apple is benefiting from the AI trade without being in the storm that the rest of the AI trade is in**.

---

## The Numbers That Matter: Closing the Gap

### The Current State of Play

As of July 16, 2026, the market cap race looks like this:

| Company | Market Cap | Gap to Nvidia |

|---------|------------|---------------|

| **Nvidia** | ~$5.05–$5.1 trillion | — |

| **Apple** | ~$4.73–$4.81 trillion | ~$320 billion (6-7%) |

| **Alphabet** | ~$4.43 trillion | ~$620 billion+ |

Apple's market capitalization now sits at roughly $4.73 trillion to $4.81 trillion, trailing only Nvidia's $5.05 trillion to $5.1 trillion valuation. A move of about 4% to roughly $340 per share would put Apple at $5 trillion.

The gap between the two companies has shrunk dramatically. On August 4, 2025, Nvidia was worth as much as **$1.37 trillion more** than Apple—the widest valuation gap since Apple lost its crown on May 2, 2025. Today, that gap has narrowed to less than $320 billion.

### The Diverging Trajectories

Two countervailing storylines are driving this shift. Wall Street has grown less enthusiastic about Nvidia, while Apple has managed to hold its ground even as questions persist about its AI direction.

Nvidia shares are up only **5.6% in 2026**, trailing the S&P 500's 9.6% gain and the Nasdaq 100's 16% rise. The stock surged roughly 270% in the first half of 2026 before pulling back, and it has shed nearly $1 trillion in market value from its May peaks amid fears of an AI spending slowdown.

Apple, by contrast, has rallied roughly **16% to 20% year-to-date**, with the stock climbing from the mid-$250s at the beginning of 2026 to around $317 to $327 by mid-July. The stock has surged 15% since its June 25 low of $275.15, adding almost **$600 billion in market value**.

**The divergence is clear**: Nvidia is underperforming the broader market despite still delivering enormous revenue growth, while Apple is outperforming as investors rotate into companies with clearer paths to consumer AI monetization.

---

## Catalyst 1: Apple's Device-First AI Strategy

### Sitting Out the Data Center Spending Spree

While hyperscalers like Microsoft, Amazon, and Alphabet collectively spend hundreds of billions on AI infrastructure, Apple has taken a fundamentally different approach. The company is using Google's Gemini to power its revamped Siri and new Apple Intelligence features, avoiding the capital-intensive buildout that has weighed on its peers' balance sheets.

This decision is increasingly viewed as a strategic advantage. As Mark Bronzo, chief investment strategist at Rye Strategic Partners, put it: "Apple is benefiting because it isn't in the storm that the rest of the AI trade is in. People are concerned about what kind of return hyperscalers could get from their AI spending".

### The Apple Intelligence Rollout

At WWDC 2026, Apple unveiled the next generation of Apple Intelligence, with Siri AI at the center—an entirely new version of Siri deeply integrated into iPhone, iPad, Mac, Apple Watch, and Apple Vision Pro. The upgraded assistant combines Apple's own intelligence models with technology developed alongside Google's Gemini AI platform.

The timing is critical. Chinese regulators this week approved Apple Intelligence for deployment on iPhones in the country, ending a two-year licensing process. Apple partnered with Alibaba and Baidu to meet China's requirement that foreign companies collaborate with local partners on AI services.

The approval could accelerate iPhone upgrades among China's base of existing users, many of whom delayed purchases pending the feature's availability. This is a significant catalyst because China accounts for about **18% of Apple's sales**.

### The Edge AI Bet

Apple's talks with startup PrismML—which has developed technology to shrink large language models to run on devices—point to a bet that the future of AI lies on the edge, not in the cloud. If successful, this approach could deliver AI capabilities at a fraction of the cost borne by competitors.

This device-first strategy is already paying off. Apple's full-year 2026 free cash flow is forecast to hit a record **$143 billion**, giving the company the financial firepower to invest aggressively in AI, repurchase billions of dollars of stock, and increase its dividend.

---

## Catalyst 2: The Coming Product Supercycle

### Apple's Most Product-Packed Year

Apple's product pipeline for the coming year is unusually dense. With a foldable iPhone expected in September, AI glasses, and major iPhone 18 Pro upgrades on the horizon, the company enters what analysts describe as its most product-packed year in recent memory—all under incoming CEO John Ternus, who takes over later this year.

### The Foldable iPhone

The foldable iPhone—reportedly set to be called the iPhone Ultra—could arrive in a passport-style format and run on Apple's A20 Pro chip. Apple has reportedly raised its foldable iPhone target to **10 million units** as it secures parts for a premium 2026-to-2027 hardware cycle.

The pricing will be strong enough to offset rising memory chip costs that forced Apple to raise prices on Macs, iPads, and Home devices in June. Despite an estimated price of close to $2,300–$2,500, analysts project strong demand for the foldable.

Combined with other iPhone models, Apple's total production orders for 2026 are expected to reach around **220 million units**.

### Beyond the Foldable

Beyond the foldable, Apple is preparing:

- **AI-equipped AirPods with cameras**

- **A major redesign of the iPad lineup**

- **Its first foray into AI glasses**

- **iPhone 18 Pro and iPhone 18 Pro Max**

J.P. Morgan analysts said past price increases have not notably affected demand, and the firm expects a **17% increase in Apple's net income** during the current fiscal year.

---

## The Services Engine: High-Margin Recurring Revenue

### A Growing Share of Revenue

Apple's services business—including the App Store, iCloud, Apple Music, AppleCare, advertising, and financial services—continues producing high-margin recurring revenue from an installed base that now exceeds **2.5 billion active devices**.

In the second quarter of fiscal 2026, services contributed **27.9% of total net sales**, with revenues rising 16.3% year over year to $30.98 billion—an all-time record in Apple's history.

### The Installed Base Advantage

Apple's strategy of maintaining iPhone prices despite rising component costs has expanded its installed base. That larger user pool feeds Apple's services business, which carries higher margins than hardware sales and creates stickiness for accessories and other Apple products.

iPhone users are also more likely to adopt other Apple products, including the Apple Watch, AirPods, and Mac, creating a cycle of ecosystem lock-in that competitors have struggled to replicate.

---

## The China Momentum: A 24% Jump in iPhone Sales

### Gaining Share While Rivals Raise Prices

Chinese smartphone shipments fell 4.3% year over year in the most recent quarter, marking the fifth consecutive period of decline. Yet Apple's iPhone sales in the country jumped **24% year over year**, the highest growth rate among all vendors in China.

The dynamics are clear: rising memory and component costs pushed most Android vendors to raise prices, which cooled upgrade demand. Apple was one of only two vendors to post growth in the quarter.

The company has absorbed higher input costs rather than passing them to consumers, stealing share from Android rivals such as Xiaomi and Oppo that were forced to raise prices as soaring demand for DRAM and NAND flash memory chips pushed component costs higher.

### The Services Flywheel

The China momentum feeds directly into Apple's services business. The company's strategy of maintaining iPhone prices despite rising component costs has expanded its installed base, which in turn drives services revenue growth.

---

## The Nvidia Vulnerability: Why the AI King Could Be Dethroned

### The Spending Slowdown Risk

Nvidia's $5.1 trillion market cap reflects investor expectations for continued AI infrastructure spending. But any sign of slowing AI adoption could pressure its valuation.

UBS analyst Mark Haefele warned of a rising risk in slowing capital expenditure growth for hyperscalers, citing shareholder pressure to justify spending. Goldman Sachs sees an end to the GPU shortage, with 60% of surveyed firms having already cut their AI spending.

### The China Headwind

Nvidia's data center sales have been hit by export restrictions to China and inventory adjustments. The company lost $4 billion of sales in China in the reported quarter. Data center revenue came in below analyst estimates for consecutive quarters.

### The Valuation Compression

Nvidia's forward price-to-earnings ratio has fallen to 18—its lowest level in seven years. The ratio is compressing because earnings are finally growing into the valuation that the market assigned years ago on pure faith.

But as Bank of America noted, the market's valuation of Nvidia implies an "unreasonable discount" on its 2027/2028 earnings per share. The market is pricing in a slowdown that may not materialize—but the perception of risk is enough to weigh on the stock.

### The Valuation Contrast

The two companies present a notable contrast. At roughly **37 times earnings, Apple commands a premium over Nvidia's approximately 30 times earnings**—even though Nvidia is expanding its top line at close to five times Apple's rate.

This is a remarkable reversal. The company with slower growth is trading at a higher multiple, suggesting investors are willing to pay more for Apple's predictable, consumer-facing business model than for Nvidia's more volatile, capital-intensive AI infrastructure play.

---

## The Path to $5 Trillion

### The Math

Apple's market cap now stands at roughly $4.8 trillion—within 5% of the $5 trillion threshold. At Wednesday's record close of $327.50, a move of about 4% to roughly $340 per share would put Apple at $5 trillion.

Multiple Wall Street analysts now project Apple will reach $5 trillion before the end of 2026. The company has already added more than half a trillion dollars in market value this month alone.

### The Catalysts

The catalysts are lined up:

1. **July 30 earnings report**: Apple reports fiscal Q3 2026 results, providing a concrete near-term catalyst. Management has guided for 14% to 17% revenue growth.

2. **Apple Intelligence rollout in China**: The approval opens a new revenue path and could accelerate iPhone upgrades.

3. **The foldable iPhone launch**: Expected in September, with supplier forecasts raised to 10 million units.

4. **The product pipeline**: AI glasses, redesigned iPad lineup, AI-equipped AirPods, and iPhone 18 Pro upgrades.

### The Historical Pattern

Apple has a long history with the market-cap crown. In August 2018, it became the first publicly traded U.S. company to reach $1 trillion. It added $2 trillion in August 2020 and $3 trillion in January 2022.

Now, Apple is on the verge of becoming the second company in history to reach $5 trillion. The company that created the smartphone market—and then reshaped it—is about to reclaim its throne.

---

## The Human Element: What This Means for Investors

### For Apple Shareholders

If you've held Apple through the AI-driven turbulence, the coming months could be rewarding. The company's 16% to 20% gain in 2026 has made it the best performer among the Magnificent Seven. The services business is growing, the China momentum is real, and the product pipeline is the strongest in years.

### For Nvidia Shareholders

Nvidia remains a phenomenal business with 85% revenue growth and a data center segment that generated more than $75 billion in a single quarter. But the stock's 5.6% gain in 2026—trailing the broader market—suggests that the easy money has been made. The market is pricing in a slowdown, and even if that slowdown doesn't materialize, the stock may struggle to regain its momentum.

### For the Average Investor

The Apple-Nvidia market cap race is more than just a curiosity. It reflects a fundamental shift in how the market is valuing AI. The companies building AI infrastructure are being rewarded, but the companies turning AI into products consumers use every day may be the bigger winners over the long term.

---

## Frequently Asked Questions

### Q: How close is Apple to surpassing Nvidia's market cap?

A: As of mid-July 2026, the gap between Apple and Nvidia stands at roughly **$190 billion to $320 billion**, or about 4% to 7%. Apple's market cap is around $4.73 trillion to $4.81 trillion, while Nvidia's is around $5.05 trillion to $5.1 trillion.

### Q: What are the main catalysts for Apple's market cap growth?

A: The two main catalysts are: 1) **Apple's device-first AI strategy**, which avoids the capital-intensive data center buildout that has weighed on competitors, and 2) **the coming product supercycle**, including a foldable iPhone, AI glasses, and major iPhone 18 Pro upgrades.

### Q: How is Apple's AI strategy different from Nvidia's?

A: Apple is paying Google for access to frontier AI models rather than building its own data centers. This device-first approach delivers AI capabilities at a fraction of the cost borne by competitors.

### Q: What's happening with Apple in China?

A: Chinese regulators approved Apple Intelligence for deployment on iPhones in the country, ending a two-year licensing process. Apple's iPhone sales in China jumped 24% year over year, the highest growth rate among all vendors.

### Q: When will Apple reach $5 trillion?

A: Multiple analysts project Apple will reach $5 trillion before the end of 2026. A move of about 4% to roughly $340 per share would put Apple at $5 trillion.

### Q: Why is Nvidia's stock underperforming despite strong earnings?

A: Nvidia is up only 5.6% in 2026 despite 85% revenue growth. Investors are worried about slowing AI capital expenditure growth and the sustainability of hyperscaler spending.

### Q: How does Apple's valuation compare to Nvidia's?

A: Apple trades at roughly 37 times earnings, while Nvidia trades at approximately 30 times earnings. Apple commands a premium despite Nvidia growing its top line at close to five times Apple's rate.

---

## Conclusion: The AI Crown Is About to Change Heads

Nvidia's reign as the world's most valuable company was built on the AI infrastructure boom. The chipmaker's data center revenue grew at triple-digit rates, and its market cap soared past $5 trillion—a milestone no company had ever reached.

But the market is beginning to recognize that the biggest opportunity may lie with the companies that turn AI into products consumers use every day. And that's where Apple comes in.

Apple's device-first AI strategy is the reason hiding in plain sight. While competitors pour hundreds of billions into data center buildouts, Apple is using Google's Gemini to power its revamped Siri and new Apple Intelligence features, avoiding the capital-intensive infrastructure that has weighed on its peers' balance sheets.

The company's 24% iPhone sales growth in China, its $143 billion in projected annual free cash flow, its 2.5 billion active devices, and its most product-packed year in recent memory are all converging to create a powerful momentum that could push Apple past $5 trillion.

The gap between Apple and Nvidia has narrowed from $1.37 trillion in August 2025 to less than $320 billion today. A move of about 4% to roughly $340 per share would put Apple at $5 trillion.

**Nvidia is still a phenomenal business with 85% revenue growth and a data center segment that generated more than $75 billion in a single quarter**. But the market's enthusiasm for AI infrastructure is waning, and the company's 5.6% gain in 2026—trailing the broader market—suggests the easy money has been made.

The AI crown is about to change heads. Apple, the company that created the smartphone market and reshaped modern life, is on the verge of becoming the world's most valuable company once again.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and company performance are subject to rapid change. Past performance is not indicative of future results. Any predictions or forecasts are speculative and may not materialize. You should consult with a qualified financial advisor before making any investment decisions. The views expressed in this article are those of the author and do not constitute a recommendation to buy or sell any security.

---

*Published: July 16, 2026*

---Read more

**Tags:** Apple, AAPL, Nvidia, NVDA, market cap, $5 trillion, AI stocks, Apple Intelligence, Siri AI, foldable iPhone, iPhone Ultra, China iPhone sales, Magnificent Seven, AI infrastructure, hyperscalers, semiconductor stocks, tech stocks, most valuable company, stock market prediction, investment analysis